Scholarlink

<p>The nitric oxide (NO)—soluble guanylate cyclase (sGC)—cyclic guanosine-monophosphate (cGMP) pathway is impaired in liver fibrosis. We investigated expression patterns of NO-sGC-cGMP components via RT-qPCR in various rat models of liver fibrosis and murine models of liver fibrosis regression. Hepatic cGMP-levels were measured chromatographically. All models demonstrated portal-hypertension and liver fibrosis, which significantly regressed in murine models. The rat models showed etiology-specific differences in NO-sGC-cGMP pathway regulation. We observed strong upregulation of sGCa1 and sGCb1 subunits in a rat choline-deficient high-fat diet model (1.75-fold, <i>p</i> = 0.004 and 2.04-fold, <i>p</i> = 0.004, respectively). The sGCa2 subunit was markedly downregulated in a rat thioacetamide model (0.66-fold, <i>p</i> = 0.026). The rat bile-duct-ligation model was characterized by strong upregulation of inducible nitric oxide synthetase (28.10-fold, <i>p</i> = 0.029). The rat thioacetamide and bile-duct-ligation models displayed downregulation of sGCb2 (0.15-fold, <i>p</i> = 0.002, and 0.19-fold, <i>p</i> = 0.029, respectively). Regardless, hepatic cGMP-levels in rat models remained unchanged. Both mouse models demonstrated upregulation of NO-sGC-cGMP pathway nodes during regression, further accompanied by increased hepatic cGMP-levels in murine carbon tetrachloride (peak-fibrosis: 3.86 nM vs. 1-week regression: 6.28 nM, <i>p</i> = 0.006; vs. 2-week regression: 5.49 nM, <i>p</i> = 0.091) and thioacetamide (peak-fibrosis: 2.87 nM vs. 1-week regression: 5.22 nM, <i>p</i> = 0.007; vs. 2-week regression: 6.68 nM, <i>p</i> &lt; 0.001) models. The NO-sGC-cGMP pathway exhibits etiology-specific and temporal regulation patterns during liver fibrogenesis and fibrosis regression. We further highlight the functional contribution of the pathway via increases in hepatic cGMP during fibrosis regression.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Molecular patterns of the NO-sGC-cGMP pathway in progressive and regressive liver fibrosis models

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月25日

查看全文
  • Thomas Sorz-Nechay,
  • Ksenia Brusilovskaya,
  • Philipp Königshofer,
  • Benedikt S. Hofer,
  • Oleksandr Petrenko,
  • Benedikt Simbrunner,
  • Vlad Taru,
  • Katharina Bonitz,
  • Henriette Horstmeier,
  • Kerstin Zinober,
  • Katharina Regnat,
  • Carolin Lackner,
  • Michael Trauner,
  • Peng Sun,
  • Ines Truebenbach,
  • Stefan G. Kauschke,
  • Philipp Schwabl,
  • Thomas Reiberger

摘要

The nitric oxide (NO)—soluble guanylate cyclase (sGC)—cyclic guanosine-monophosphate (cGMP) pathway is impaired in liver fibrosis. We investigated expression patterns of NO-sGC-cGMP components via RT-qPCR in various rat models of liver fibrosis and murine models of liver fibrosis regression. Hepatic cGMP-levels were measured chromatographically. All models demonstrated portal-hypertension and liver fibrosis, which significantly regressed in murine models. The rat models showed etiology-specific differences in NO-sGC-cGMP pathway regulation. We observed strong upregulation of sGCa1 and sGCb1 subunits in a rat choline-deficient high-fat diet model (1.75-fold, p = 0.004 and 2.04-fold, p = 0.004, respectively). The sGCa2 subunit was markedly downregulated in a rat thioacetamide model (0.66-fold, p = 0.026). The rat bile-duct-ligation model was characterized by strong upregulation of inducible nitric oxide synthetase (28.10-fold, p = 0.029). The rat thioacetamide and bile-duct-ligation models displayed downregulation of sGCb2 (0.15-fold, p = 0.002, and 0.19-fold, p = 0.029, respectively). Regardless, hepatic cGMP-levels in rat models remained unchanged. Both mouse models demonstrated upregulation of NO-sGC-cGMP pathway nodes during regression, further accompanied by increased hepatic cGMP-levels in murine carbon tetrachloride (peak-fibrosis: 3.86 nM vs. 1-week regression: 6.28 nM, p = 0.006; vs. 2-week regression: 5.49 nM, p = 0.091) and thioacetamide (peak-fibrosis: 2.87 nM vs. 1-week regression: 5.22 nM, p = 0.007; vs. 2-week regression: 6.68 nM, p < 0.001) models. The NO-sGC-cGMP pathway exhibits etiology-specific and temporal regulation patterns during liver fibrogenesis and fibrosis regression. We further highlight the functional contribution of the pathway via increases in hepatic cGMP during fibrosis regression.

Graphical abstract